Company
Every investor coverage indicates participated in a round Accellacare raised.
Companies Accellacare acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Accellacare. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.